---
title: Intuitive Surgical, Inc. (ISRG)
layout: default
nav_order: 57
---

# Intuitive Surgical, Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 4/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $87.226 B

Intuitive Surgical dominates the robotic surgery market with its da Vinci Surgical System.  While its past performance has been stellar, a deeper dive reveals potential cracks in its moat's armor.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=ISRG+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/ISRG/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (4/5):**

Intuitive enjoys a wide moat, primarily due to high customer switching costs and a network effect.

* **Switching Costs:** Hospitals that invest in the da Vinci system incur significant costs beyond the initial purchase, including surgeon training, recurring maintenance, and integration with other hospital systems.  Switching to a competitor would mean retraining surgeons, purchasing new equipment, and potentially disrupting workflows, creating substantial monetary and time costs.  This stickiness is a significant deterrent for customers considering switching.
* **Network Effect:** The more da Vinci systems installed, the greater the incentive for surgeons to become trained on it, as it becomes the industry standard. Similarly, more systems placed increase the urgency for Intuitive to provide more training, ancillary support, and accessories. More procedures performed lead to improvement of its products, which in turn attracts more users. This network effect is very powerful and, as discussed in Pat Dorsey’s *The Little Book That Builds Wealth*, is responsible for the creation of several natural monopolies and oligopolies.

However, potential threats exist:

* **Competition:** While Intuitive's market share is dominant, new entrants are emerging, offering potentially cheaper and more portable options. While these may not provide the same range of features, the cost-conscious nature of hospital budgets may give them a foothold. As Micheal Burry discusses in his online articles, "the market is often “more wrong””, meaning that investors tend to be overly optimistic or pessimistic. Competition can erode earnings growth over the long term.
* **Technological Disruption:**  As with any technology-based company, there is always the risk of disruptive innovation.  A simpler, cheaper, or easier-to-use system could emerge, potentially weakening Intuitive's competitive position. The shift toward digital has already changed the competitive scene. As discussed in *Measuring the Moat*, being technologically supplanted is one of the biggest risks faced by technology companies.
* **Regulations and Reimbursements:**  Changes in regulations or reimbursement policies regarding robotic surgery could affect Intuitive’s profitability and consequently its value. 

**Management (3/5):**

While Intuitive's management has overseen tremendous growth, a closer look reveals some potential concerns:

* **Capital Allocation:**  While the company has historically been good at reinvesting in growth, concerns arise regarding acquisitions and investments outside its core business. The company’s acquisition of Orpheus Medical in 2020 has not generated significant returns, and questions remain about management's ability to effectively deploy capital in non-core businesses. This is similar to the challenges Michael Burry had faced with his investments, as mentioned in his articles.
* **Insider Ownership:** Insider ownership is relatively low, potentially weakening management's alignment with shareholder interests.
* **Communication:** While Intuitive's management does disclose some financial information, a review of the company's conference calls and 10K filings reveals limited information about long-term strategic goals. A lack of clear communication about its capital allocation decisions raises concerns about its focus on long-term value creation. (Q2 2023, Q3 2023, Q4 2023 and Q1 2024 ISRG Earnings Calls) (2021, 2022, and 2023 Intuitive Surgical 10-K Filings)

**Catalyst (2/5):**

* **Expansion into New Procedures:** Intuitive is continuously expanding the da Vinci's application into new surgical procedures. Success in these expansions could drive procedure volumes and system sales, thus leading to a higher value for the company. The success of Ion, the robotic-assisted platform for minimally invasive lung biopsies, is a potential catalyst. The company is also pursuing approvals for its robotic stapler in the US and other countries, which could further propel growth in its existing procedures.
* **International Expansion:**  Growing adoption of robotic surgery in international markets, particularly in Asia, is a potential catalyst.  However, competition from local and global players in these markets poses a challenge.


**Valuation ($87.226 Billion):**

{: .note }

I used a three-stage discounted cash flow (DCF) model to estimate a fair value for Intuitive Surgical.

**Assumptions:**

* **Revenue Growth:** 15% for the first 5 years, 8% for the next 5 years, and 3% thereafter. This is a pessimistic forecast, given the company’s historical growth rates and analyst expectations.
* **Operating Margin:** 30% in stable growth. This is a conservative estimate, given the company's current margins and the potential for margin compression due to competition.
* **Reinvestment Rate:** 50% during the high-growth period, declining to 30% in stable growth. This reflects a gradual reduction in capital expenditures as growth slows.
* **Cost of Capital:** 11%, based on a risk-free rate of 4.78% (10-year treasury bond rate), a beta of 1.73 (Bloomberg, adjusted for a five-year period as described in The Intelligent Investor), and a risk premium of 4%.

**Calculations:**

* **Terminal Value:** The terminal value at the end of year 10 is calculated using the stable growth perpetuity formula:
     Terminal value = (Net Income in year 11 / (Cost of Capital - Stable Growth Rate)).
* **Present Value of Cash Flows:** Discounted free cash flows and terminal value to the present, using a WACC of 11%.
* **Value of Operating Assets:** $87.226 Billion

{: .important }

This valuation is lower than the current market capitalization, suggesting that the stock may be slightly overvalued.  However, given the company's strong competitive position and growth potential, a small premium to fair value may be justified.


**Recent Concerns:**

* **Procedure Slowdown from COVID-19:** The COVID-19 pandemic led to a decline in da Vinci procedures, as discussed extensively in the 2020 and 2021 earnings calls. Although procedure volumes have rebounded, concerns remain about the long-term impact of the pandemic on hospital capital spending. Management discussed extensively about this issue in the Q4 2020 earnings call.
* **Competition:**  New entrants are emerging in the robotic surgery market, and some established medical device companies are also developing their own robotic surgery platforms.  This competition could put pressure on Intuitive's pricing and margins. In the Q3 2023 earnings call, management discussed competition from Medtronic, Johnson & Johnson, and Zimmer Biomet.


**Conclusion:**

Intuitive Surgical is a dominant player in a rapidly growing market. Its wide moat, driven by high switching costs and a network effect, gives it a strong competitive advantage. However, potential threats from competition and technological disruption, along with a slightly stretched valuation, warrant caution.  Management's capital allocation decisions and communication regarding long-term value creation also merit scrutiny.  The stock may be worth considering on dips, but investors should avoid chasing the stock higher.